<DOC>
	<DOC>NCT01106560</DOC>
	<brief_summary>This is a single-centre, randomised, prospective clinical follow-up study to evaluate clinical outcome and gait analysis after total hip arthroplasty using the standard postero-lateral approach or the minimally invasive anterior approach.</brief_summary>
	<brief_title>A Randomised Trial Comparing Anterior Versus Posterior Approach in Total Hip Replacement</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Males and females aged 1875 years at time of surgery. Those presenting with primary or secondary osteoarthritis and/or rheumatoid arthritis of the hip. Those deemed capable of giving informed consent, understanding the aims of the study and expressing willingness to comply with the postoperative review programme. Patients who signed the study consent form prior to surgery. Pregnant women or women who plan to conceive in the future. Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems. Those already treated by with a Total Hip Replacement (THR) (i.e. requiring a revision hip replacement). Those with coexistent ipsilateral knee disease or back problems Muscle contracture around the hip joint Individuals who have undergone organ transplant. Those with a known coexistent medical condition where death is anticipated within five years due to the preexisting medical condition. Individuals who have had a THR on the contralateral side within the 6 months. Individuals who have undergone a THR on the contralateral side and whose outcome is considered unsatisfactory or not good. An unsatisfactory or poor result is defined as achieving a total UCLA score (including activity) &lt; 16 points. Individuals requiring bilateral hip replacement. Individuals whose body mass index (BMI; kg/m2) &gt;35. Individuals with active or suspected infection or sepsis. Individuals with renal failure and/or renal insufficiency. Patients with severe forms of developmental dysplasia of the hip (DDH): Crowe types II, III, IV.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>